{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:25:49Z","timestamp":1791318349930,"version":"4.3.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"},{"name":"Kyowa Kirin Co., Ltd"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson\u2019s disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and \u22651 NMS.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Dopamine agonists were the most frequently prescribed drugs combined with levodopa-containing drugs, followed by entacapone, zonisamide, istradefylline, selegiline, and amantadine. The daily dose of levodopa-containing drugs, rotigotine, entacapone, istradefylline, and droxidopa, and the levodopa-equivalent dose increased during the observation period. In a subgroup analysis of patients stratified by NMS status (improved\/unchanged\/deteriorated), the deteriorated group had higher prescription rates of entacapone and istradefylline, whereas the improved group had higher prescription rates of NSAIDs and zonisamide at Week 52. Prescriptions varied by geographical region for anti-PD drugs and by NMS status for NSAIDs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>There were significant changes in the prescriptions and dosing of selected anti-PD drugs, especially newer drugs. Anti-PD drug and NSAID prescriptions also varied by changes in NMS status and geographic region.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0309297","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:30:56Z","timestamp":1729704656000},"page":"e0309297","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prescription trends in Japanese advanced Parkinson\u2019s disease patients with non-motor symptoms: J-FIRST"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8690-3151","authenticated-orcid":true,"given":"Masahiro","family":"Nomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Wei","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemoto","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the J-FIRST Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"pone.0309297.ref001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41531-018-0069-x","article-title":"Risk factors of levodopa-induced dyskinesia in Parkinson\u2019s disease: results from the PPMI cohort","volume":"4","author":"P Eusebi","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"pone.0309297.ref002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-0037-1602423","article-title":"Motor complications of dopaminergic medications in Parkinson\u2019s disease","volume":"37","author":"ME Freitas","year":"2017","journal-title":"Semin Neurol"},{"issue":"6","key":"pone.0309297.ref003","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","article-title":"Risk factors for non-motor symptoms in Parkinson\u2019s disease","volume":"17","author":"J Marinus","year":"2018","journal-title":"Lancet Neurol"},{"issue":"5","key":"pone.0309297.ref004","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/ene.12950","article-title":"The impact of non-motor symptoms on the quality of life of Parkinson\u2019s disease patients: a longitudinal study","volume":"23","author":"KM Prakash","year":"2016","journal-title":"Eur J Neurol"},{"issue":"7","key":"pone.0309297.ref005","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/ene.14221","article-title":"Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson\u2019s disease","volume":"27","author":"D Santos-Garc\u00eda","year":"2020","journal-title":"Eur J Neurol"},{"issue":"7","key":"pone.0309297.ref006","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"AHV Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"pone.0309297.ref007","unstructured":"Japanese Society of Neurology, Parkinson\u2019s disease clinical practice guidelines 2018. Available from: https:\/\/www.neurology-jp.org\/guidelinem\/parkinson_2018.html. Accessed December 3, 2022. In Japanese."},{"key":"pone.0309297.ref008","doi-asserted-by":"crossref","first-page":"100257","DOI":"10.1016\/j.ensci.2020.100257","article-title":"Prescription pattern of anti-Parkinson\u2019s disease drugs in Japan based on a nationwide medical claims database","volume":"20","author":"M Suzuki","year":"2020","journal-title":"eNeurologicalSci"},{"issue":"4","key":"pone.0309297.ref009","doi-asserted-by":"crossref","first-page":"e0230213","DOI":"10.1371\/journal.pone.0230213","article-title":"Adherence to treatment guideline recommendations for Parkinson\u2019s disease in Japan: a longitudinal analysis of a nationwide medical claims database between 2008 and 2016","volume":"15","author":"M Suzuki","year":"2020","journal-title":"PLoS One"},{"key":"pone.0309297.ref010","first-page":"100144","article-title":"Difference in rural and urban Medicare prescription pattern for Parkinson\u2019s disease in Hawai\u2019i","volume":"6","author":"MK Bruno","year":"2022","journal-title":"Clin Park Relat Disord"},{"issue":"11","key":"pone.0309297.ref011","doi-asserted-by":"crossref","first-page":"e0225723","DOI":"10.1371\/journal.pone.0225723","article-title":"The characteristics and treatment patterns of patients with Parkinson\u2019s disease in the United States and United Kingdom: A retrospective cohort study","volume":"14","author":"L Kalilani","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"pone.0309297.ref012","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/mds.23038","article-title":"Prescribing patterns of antiparkinsonian agents in Europe","volume":"25","author":"MM Rosa","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"pone.0309297.ref013","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.expneurol.2007.02.008","article-title":"Non-steroidal anti-inflammatory drugs in Parkinson\u2019s disease","volume":"205","author":"E Esposito","year":"2007","journal-title":"Exp Neurol"},{"issue":"9","key":"pone.0309297.ref014","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41582-020-0394-7","article-title":"Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease","volume":"16","author":"I Fyfe","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"pone.0309297.ref015","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/mds.28189","article-title":"Nonsteroidal anti-inflammatory use and LRRK2 Parkinson\u2019s disease penetrance","volume":"35","author":"M San Luciano","year":"2020","journal-title":"Mov Disord"},{"issue":"1","key":"pone.0309297.ref016","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10787-020-00764-w","article-title":"Neuroinflammatory responses in Parkinson\u2019s disease: relevance of ibuprofen in therapeutics","volume":"29","author":"A Singh","year":"2021","journal-title":"Inflammopharmacology"},{"issue":"5","key":"pone.0309297.ref017","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S1734-1140(13)71480-4","article-title":"Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson\u2019s disease","volume":"65","author":"M Swi\u0105tkiewicz","year":"2013","journal-title":"Pharmacol Rep"},{"key":"pone.0309297.ref018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2017.02.024","article-title":"Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson\u2019s disease patients from 35 medical centers","volume":"38","author":"T Maeda","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"pone.0309297.ref019","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mdc3.12939","article-title":"Real-world nonmotor changes in patients with Parkinson\u2019s disease and motor fluctuations: J-FIRST","volume":"7","author":"H Watanabe","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"pone.0309297.ref020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.parkreldis.2021.09.015","article-title":"Influence of istradefylline on non-motor symptoms of Parkinson\u2019s disease: A subanalysis of a 1-year observational study in Japan (J-FIRST)","volume":"91","author":"Y Shimo","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0309297.ref021","doi-asserted-by":"crossref","first-page":"120619","DOI":"10.1016\/j.jns.2023.120619","article-title":"Risk factors for developing dyskinesia among Parkinson\u2019s disease patients with wearing-off: J-FIRST","volume":"448","author":"T Mishima","year":"2023","journal-title":"J Neurol Sci"},{"issue":"8","key":"pone.0309297.ref022","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/11206750-000000000-00000","article-title":"Rotigotine transdermal patch: a review of its use in the treatment of Parkinson\u2019s disease","volume":"25","author":"M Sanford","year":"2011","journal-title":"CNS Drugs"},{"issue":"12","key":"pone.0309297.ref023","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1586\/14737175.2013.859986","article-title":"Effects of rotigotine transdermal system on non-motor symptoms in Parkinson\u2019s disease: an overview","volume":"13","author":"TA Zesiewicz","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"pone.0309297.ref024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study","volume":"62","author":"Parkinson Study Group","year":"2005","journal-title":"Arch Neurol"},{"issue":"10","key":"pone.0309297.ref025","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease","volume":"29","author":"R Borgohain","year":"2014","journal-title":"Mov Disord"},{"issue":"2","key":"pone.0309297.ref026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","article-title":"Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"AJ Lees","year":"2017","journal-title":"JAMA Neurol"},{"issue":"2","key":"pone.0309297.ref027","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.parkreldis.2011.09.023","article-title":"Istradefylline for Parkinson\u2019s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study","volume":"18","author":"E Pourcher","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0309297.ref028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.04.025","article-title":"Efficacy and safety of adjunctive rasagiline in Japanese Parkinson\u2019s disease patients with wearing-off phenomena: a phase 2\/3, randomized, double-blind, placebo-controlled, multicenter study","volume":"53","author":"N Hattori","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0309297.ref029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","article-title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study","volume":"75","author":"N Hattori","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"pone.0309297.ref030","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","article-title":"Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: a randomized, controlled study","volume":"25","author":"Y Mizuno","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"pone.0309297.ref031","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/mds.28322","article-title":"Randomized, controlled study of opicapone in Japanese parkinson\u2019s patients with motor fluctuations","volume":"36","author":"A Takeda","year":"2021","journal-title":"Mov Disord"},{"issue":"2","key":"pone.0309297.ref032","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3999\/jscpt.42.59","article-title":"International differences in approved and used dosing for drugs","volume":"42","author":"M. Nagai","year":"2011","journal-title":"Jpn J Clin Pharmacol Ther"},{"issue":"10","key":"pone.0309297.ref033","doi-asserted-by":"crossref","first-page":"e47387","DOI":"10.1371\/journal.pone.0047387","article-title":"Non-motor symptoms in patients with Parkinson\u2019s disease\u2014correlations with inflammatory cytokines in serum","volume":"7","author":"D Lindqvist","year":"2012","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:31:11Z","timestamp":1729704671000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309297"}},"subtitle":[],"editor":[{"given":"Calogero Edoardo","family":"Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309297","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}